Loading clinical trials...
Loading clinical trials...
Multicentre, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Effect of a 30-week Caffeine Treatment on Cognition in Alzheimer's Disease at Beginning to Moderate Stages
Conditions
Interventions
Caffeine
Placebo
Locations
17
France
CHU Amiens
Amiens, France
CH Arras
Arras, France
CH Beauvais
Beauvais, France
CH Béthune
Béthune, France
CHU Caen
Caen, France
CH Calais
Calais, France
Start Date
March 1, 2021
Primary Completion Date
December 1, 2027
Completion Date
December 1, 2027
Last Updated
April 20, 2026
NCT07545473
NCT07531732
NCT07290387
NCT06501495
NCT06121544
NCT06657768
Lead Sponsor
University Hospital, Lille
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions